Antibody responses against NY-ESO-1 and HER2 antigens in patients vaccinated with combinations of cholesteryl pullulan (CHP)-NY-ESO-1 and CHP-HER2 with OK-432.
Combination vaccines of the NY-ESO-1 protein complexed with cholesteryl pullulan (CHP), CHP-NY-ESO-1, and the truncated 146HER2 protein with CHP, CHP-HER2, were subcutaneously administered with the immuno-adjuvant OK-432 to eight esophageal cancer patients. Vaccination was well-tolerated. NY-ESO-1- and HER2-specific antibody responses were analyzed using the patients' sera and samples from previous single CHP-NY-ESO-1 or CHP-HER2 vaccine trial. The responses to NY-ESO-1 in the combination vaccine study were comparable to the single vaccine. For responses to HER2, there were fewer antibody responses in the combination vaccines. Although there were marked individual variations in the antibody responses to the NY-ESO-1 and HER2 antigens, the reaction patterns to these antigens were comparable within each patient. Antibodies to OK-432 were not augmented. Protein cancer vaccines targeting multiple antigens are feasible.
Aoki
Masatoshi
M
Department of Haematology and Oncology, Mie University Graduate School of Medicine, 2-174, Edobashi, Tsu, Mie 514-8507, Japan. aoki@kaiseihp.com
Ueda
Shugo
S
Nishikawa
Hiroyoshi
H
Kitano
Shigehisa
S
Hirayama
Michiko
M
Ikeda
Hiroaki
H
Toyoda
Hideki
H
Tanaka
Kyosuke
K
Kanai
Michiyuki
M
Takabayashi
Arimichi
A
Imai
Hiroshi
H
Shiraishi
Taizo
T
Sato
Eiichi
E
Wada
Hisashi
H
Nakayama
Eiichi
E
Takei
Yoshiyuki
Y
Katayama
Naoyuki
N
Shiku
Hiroshi
H
Kageyama
Shinichi
S
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000368:Aged; D000912:Antibodies, Neoplasm / Q000097:blood; D000917:Antibody Formation; D000918:Antibody Specificity; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D004938:Esophageal Neoplasms / Q000628:therapy; D005260:Female; D005936:Glucans / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008565:Membrane Proteins / Q000276:immunology*; D008875:Middle Aged; D010844:Picibanil / Q000276:immunology*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000276:immunology*; D011994:Recombinant Proteins / Q000276:immunology; D017778:Vaccines, Combined / Q000276:immunology
D000276:Adjuvants, Immunologic; D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D005936:Glucans; D007074:Immunoglobulin G; D008565:Membrane Proteins; D010844:Picibanil; D018719:Erb-b2 Receptor Tyrosine Kinases; D011994:Recombinant Proteins; D017778:Vaccines, Combined; C528170:CHP-HER2 vaccine; C104948:CTAG1B protein, human; C009109:pullulan